U.S. FDA approves first mRNA flu shot from Moderna

The U.S. FDA's approval of Moderna's mRNA flu shot marks a significant milestone, marking the first time an mRNA vaccine has been authorized for flu prevention in adults aged 50 and over. This decision reverses a previous refusal and highlights the potential of mRNA technology in combating seasonal influenza. The approval comes as Health Canada is also considering its own approval, potentially paving the way for a new standard in flu prevention. This move could transform how flu vaccines are developed and administered, leveraging the same technology that revolutionized COVID-19 shots.